Cancer Angiogenesis Inhibitors Market Size, Share, VEGF Therapy Trends and Forecast 2035

Cancer Angiogenesis Inhibitors Market Size and Forecast 2026-2035

The global cancer angiogenesis inhibitors market is estimated at USD 16.85 billion in 2025 and is forecast to reach USD 38.45 billion by 2035, expanding at a modeled CAGR of 8.6% during 2026-2035.

The 2025 estimate reflects the commercial scale already visible across major franchises. Exelixis reported USD 2.9 billion in global cabozantinib franchise sales during 2025, while Roche reported CHF 973 million of Avastin sales despite continued biosimilar erosion. Eisai reported USD 1.505 billion in U.S. Lenvima revenue for its fiscal year ended March 2025.

The addressable market extends well beyond these three brands through bevacizumab biosimilars, axitinib, sunitinib, pazopanib, ramucirumab, regorafenib, sorafenib, fruquintinib, ziv-aflibercept and other VEGF/VEGFR-directed agents.

NCI identifies VEGF and VEGFR as the principal targets of approved cancer angiogenesis inhibitors and lists therapies including bevacizumab, axitinib, cabozantinib, lenvatinib, pazopanib, ramucirumab, regorafenib, sorafenib, sunitinib and ziv-aflibercept among established antiangiogenic drugs.

Global Cancer Angiogenesis Inhibitors Market Highlights

• 2025 Market Size: USD 16.85 Billion
• 2035 Forecast Market Size: USD 38.45 Billion
• CAGR, 2026-2035: 8.6%
• Largest Region: North America - 43.0% share
• Fastest-Growing Region: Asia-Pacific
• Leading Therapy Class: VEGFR/Multikinase TKIs - 58.4% modeled share
• Largest Cancer Segment: Renal Cell Carcinoma - 24.8% modeled share
• Key Emerging Technology: PD-1/VEGF bispecific antibodies

Cancer Angiogenesis Inhibitors Market Definition

Angiogenesis is the formation of new blood vessels. Tumors require vascular supply to obtain oxygen and nutrients as they grow.

Many cancers increase production of vascular endothelial growth factor (VEGF) or activate related signaling pathways to stimulate tumor-associated blood-vessel formation.

Angiogenesis inhibitors interfere with this process.

Bevacizumab, for example, binds VEGF and prevents the growth and maintenance of tumor blood vessels. Ramucirumab instead targets VEGFR-2, preventing VEGF signaling through an important endothelial-cell receptor.

Small-molecule TKIs such as cabozantinib, lenvatinib, axitinib and fruquintinib inhibit VEGFR signaling intracellularly and may simultaneously target additional kinases involved in tumor proliferation or resistance.

This refreshed market excludes ophthalmic VEGF inhibitors used for age-related macular degeneration, diabetic macular edema and retinal disease.

It also avoids treating every therapy with an incidental antiangiogenic effect as part of the core market. The commercial focus is on medicines for which VEGF/VEGFR inhibition or tumor-vascular suppression represents a material component of their anticancer mechanism.

Cancer Angiogenesis Inhibitors Market Key Takeaways

• VEGF/VEGFR remains the commercial center of the market. NCI notes that most approved angiogenesis inhibitors were designed specifically to block VEGF, VEGF receptors or related angiogenic pathways.
• Small-molecule VEGFR and multikinase inhibitors are estimated to generate 58.4% of 2025 market revenue, reflecting the scale of cabozantinib, lenvatinib, axitinib and several established generic TKIs.
• Antibodies and biosimilars account for 35.2%, with bevacizumab forming the largest volume platform and ramucirumab providing additional VEGFR-2-directed revenue.
• Bevacizumab is entering a mature biosimilar phase. In April 2025, FDA approved Biocon Biologics' Jobevne, another bevacizumab biosimilar, for multiple Avastin oncology indications. Biocon noted that U.S. bevacizumab sales were USD 2 billion in 2023.
• The oral TKI market remains innovative despite several mature products. Cabozantinib gained a new U.S. neuroendocrine-tumor indication in March 2025, while Exelixis' next-generation VEGFR/MET/TAM inhibitor zanzalintinib is under FDA review in previously treated metastatic colorectal cancer.

White-Space Opportunity: PD-1 × VEGF Bispecific Antibodies Could Collapse Two Drug Classes into One

The most disruptive development in the market is the emergence of antibodies that combine immune checkpoint inhibition and VEGF blockade within one molecule.

The leading example is ivonescimab, a tetravalent bispecific antibody targeting both PD-1 and VEGF.

This matters because antiangiogenic therapy and immune checkpoint blockade are already used together across several solid-tumor settings. A bispecific molecule potentially integrates those two mechanisms into a single engineered drug.

The commercial implications extend beyond convenience.

VEGF contributes not only to blood-vessel formation but also to an immunosuppressive tumor microenvironment. Combining VEGF inhibition with PD-1 blockade may therefore simultaneously normalize tumor vasculature and enhance antitumor immune activity.

Ivonescimab is already commercially relevant in China. On August 12, 2026, Akeso announced Chinese approval of ivonescimab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer.

The U.S. opportunity is also moving rapidly.

Summit Therapeutics' BLA for ivonescimab plus chemotherapy in previously treated EGFR-mutated non-squamous NSCLC has been accepted by FDA, with a November 14, 2026 PDUFA target date.

Meanwhile, the global Phase III HARMONi-3 study is directly comparing ivonescimab plus chemotherapy with pembrolizumab plus chemotherapy in 1,600 first-line metastatic NSCLC patients.

If PD-1×VEGF bispecific antibodies demonstrate consistent superiority or clinically meaningful advantages over separately administered checkpoint and antiangiogenic agents, the market could shift from:

checkpoint inhibitor + anti-VEGF drug

toward:

single-molecule immune checkpoint + angiogenesis blockade.

That would create an entirely new competitive category inside both the angiogenesis and immuno-oncology markets.

Cancer Angiogenesis Inhibitors Market Trends

Antiangiogenic Therapy Is Increasingly Combined with Immunotherapy

One of the biggest changes in oncology has been the transition from angiogenesis inhibitors used predominantly with chemotherapy toward combinations with checkpoint inhibitors.

Lenvatinib is approved with pembrolizumab in advanced renal cell carcinoma and selected advanced endometrial carcinoma, while cabozantinib is used with nivolumab in first-line advanced RCC.

The biological rationale is increasingly important commercially.

Anti-VEGF therapy may alter vascular permeability and the tumor microenvironment, while checkpoint blockade activates antitumor immune responses. Combining the two can create a complementary strategy rather than simply adding another cytotoxic drug.

This convergence is now progressing further through PD-1×VEGF bispecific antibodies.

Cabozantinib Continues to Expand Beyond Kidney and Liver Cancer

Cabozantinib has become one of the largest VEGFR/multikinase TKI franchises globally.

Exelixis reported USD 2.9 billion in global cabozantinib franchise net product revenue during 2025, with USD 2.12 billion generated in the United States.

On March 26, 2025, FDA approved Cabometyx for previously treated, unresectable or metastatic well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors.

In the CABINET trial, median progression-free survival in pancreatic NET reached 13.8 months with cabozantinib versus 3.3 months with placebo.

The approval demonstrates how established angiogenesis inhibitors can continue growing through indication expansion even after becoming standard therapies in mature markets such as RCC.

Zanzalintinib Could Become the Next Major VEGFR TKI Franchise

Exelixis is developing zanzalintinib, an oral inhibitor targeting VEGFRs together with MET and the TAM kinases TYRO3, AXL and MER.

FDA accepted the company's NDA in February 2026 for zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer and assigned a December 3, 2026 PDUFA action date.

The application is based on the Phase III STELLAR-303 program, which demonstrated a statistically significant overall-survival improvement in the overall intent-to-treat population versus regorafenib.

The strategic significance extends beyond colorectal cancer.

Zanzalintinib is also under development in kidney cancer, neuroendocrine tumors and other solid tumors, potentially creating a next-generation franchise after cabozantinib.

Bevacizumab Biosimilars Are Expanding Access While Pressuring Revenue

Bevacizumab remains one of the most broadly applicable antiangiogenic biologics.

NCI currently lists bevacizumab brands including Avastin, Alymsys, Jobevne, Mvasi and Zirabev and describes approved cancer uses spanning colorectal, cervical, lung, renal and gynecological malignancies.

The commercial structure is nevertheless changing rapidly.

Roche reported CHF 973 million of Avastin sales in 2025, down 17% at constant exchange rates, reflecting continuing biosimilar erosion.

At the same time, biosimilar competition broadens patient access and supports continued bevacizumab treatment volume.

Biocon's Jobevne became another U.S.-approved bevacizumab biosimilar in April 2025, reinforcing the shift from a single blockbuster brand toward a multi-supplier anti-VEGF molecule market.

This creates an unusual market dynamic: bevacizumab treatment volume can remain resilient or expand even while average revenue per dose declines.

Lenvatinib Remains One of the Largest Multi-Indication Antiangiogenic Drugs

Lenvatinib inhibits several receptor tyrosine kinases, including VEGFRs, and is used across differentiated thyroid cancer, hepatocellular carcinoma, renal cell carcinoma and endometrial carcinoma.

Its current U.S. label includes pembrolizumab combinations in advanced RCC and selected advanced endometrial cancer.

Eisai reported USD 1.505 billion in U.S. Lenvima revenue alone for the fiscal year ended March 31, 2025.

Patent protection is also commercially important. Eisai reported that settlements with certain generic applicants permit U.S. entry from July 2030 under specified conditions, while litigation involving another generic manufacturer could extend relevant protection further.

The expected arrival of generic lenvatinib around the next decade therefore represents an important forecast variable for the market.

Colorectal Cancer Is Becoming a Competitive Late-Line VEGFR Market

Antiangiogenic treatment has long been established in metastatic colorectal cancer through bevacizumab, ramucirumab and ziv-aflibercept.

The oral TKI market is now becoming more competitive.

Fruquintinib is approved in previously treated metastatic colorectal cancer following prior chemotherapy and anti-VEGF treatment. Its current FDA label retains that indication.

Zanzalintinib could add another competitor if approved following its December 2026 FDA review.

This makes refractory colorectal cancer one of the clearest examples of angiogenesis inhibitors becoming sequenced across multiple lines rather than used only once.

Antiangiogenic Therapy Is Expanding in Neuroendocrine Tumors

Neuroendocrine tumors have become a meaningful new application for antiangiogenic TKIs.

Cabometyx's March 2025 approval covers previously treated pancreatic and extra-pancreatic NETs and gives Exelixis a differentiated indication outside its traditional RCC and HCC markets.

The response illustrates a wider trend: rare and molecularly distinct solid tumors can support high-value angiogenesis products even when absolute patient numbers are much smaller than in lung or colorectal cancer.

Cancer Angiogenesis Inhibitors Market Scope

Cancer Angiogenesis Inhibitors Market Disruption Analysis

The first major disruption is the fusion of antiangiogenesis with immunotherapy.

Historically, pharmaceutical companies combined two separate medicines-for example, a checkpoint inhibitor and a VEGFR TKI.

Ivonescimab introduces the possibility that checkpoint and VEGF inhibition can exist within one molecule. The drug's Chinese approval on August 12, 2026, and ongoing U.S. regulatory review make this more than a theoretical pipeline concept.

The second disruption is biosimilarization.

Avastin established the anti-VEGF antibody market, but multiple bevacizumab biosimilars now compete in major economies. Roche's declining Avastin sales and Biocon's 2025 Jobevne approval illustrate the accelerating transition.

The third disruption is next-generation oral VEGFR inhibition.

Zanzalintinib demonstrates that companies can redesign mature VEGFR TKI mechanisms to influence additional resistance and immune pathways.

The fourth disruption is combination sequencing.

A patient may now receive one VEGF inhibitor in first-line treatment, another angiogenesis inhibitor after progression and a different antiangiogenic modality later.

This changes the commercial question from whether an angiogenesis inhibitor is used to which inhibitor is used at each disease stage.

Cancer Angiogenesis Inhibitors Market Dynamics

Global Cancer Burden Supports Long-Term Demand

Worldwide cancer incidence remains enormous.

IARC's global estimates identify lung and colorectal cancer among the most frequently diagnosed malignancies and place lung, colorectal and liver cancer among the leading causes of cancer mortality.

These are also major tumor types in which antiangiogenic drugs play established or emerging therapeutic roles.

Demand therefore depends both on growing cancer prevalence and on the number of treatment lines in which VEGF/VEGFR therapy is incorporated.

Multiple Indications Increase Franchise Durability

Unlike narrowly targeted precision-oncology therapies, several angiogenesis inhibitors work across multiple histologies.

Bevacizumab is used across several major solid tumors. Cabozantinib spans RCC, HCC and NETs. Lenvatinib is used across thyroid, kidney, liver and endometrial cancers.

This multi-indication structure allows successful agents to continue expanding despite competition within individual cancers.

Oral TKIs Reduce Infusion Dependence

Bevacizumab and ramucirumab require intravenous administration.

VEGFR TKIs such as lenvatinib, cabozantinib, axitinib and fruquintinib are orally administered, allowing treatment outside infusion centers.

This provides an important convenience advantage, particularly as antiangiogenic therapies are administered for prolonged periods.

Biosimilar Competition Is the Principal Pricing Restraint

Avastin demonstrates the revenue pressure produced when a major antiangiogenic biologic loses exclusivity.

Roche's global Avastin sales declined to CHF 973 million in 2025, while the number of available bevacizumab biosimilars continued increasing.

Biosimilars can expand access but reduce average selling prices and shift procurement toward payer contracts and institutional tendering.

Toxicity Limits Patient Selection

VEGF inhibition is associated with a distinct toxicity profile.

NCI identifies hypertension, bleeding, arterial thromboembolic events, impaired wound healing, proteinuria and rare gastrointestinal perforation or fistula among recognized complications of VEGF-targeted angiogenesis inhibitors.

VEGFR TKIs can additionally cause fatigue, diarrhea, hand-foot syndrome, hypothyroidism and cardiac effects.

These adverse effects can limit treatment duration and are especially important when antiangiogenic drugs are combined with immunotherapy.

Cancer Angiogenesis Inhibitors Market Segment Analysis

VEGFR and Multikinase TKIs Lead with 58.4%

VEGFR and multikinase TKIs are estimated to account for 58.4% of global market revenue in 2025, equivalent to around USD 9.84 billion.

The segment includes cabozantinib, lenvatinib, axitinib, fruquintinib, pazopanib, regorafenib, sorafenib and sunitinib.

Its leadership reflects both broad cancer coverage and relatively high branded prices for newer agents.

Cabozantinib alone generated USD 2.9 billion globally in 2025, while U.S. Lenvima revenue exceeded USD 1.5 billion during Eisai's fiscal year ended March 2025.

The category should retain leadership through 2035, supported by next-generation agents such as zanzalintinib.

Anti-VEGF and VEGFR Antibodies Account for 35.2%

Monoclonal antibodies and bevacizumab biosimilars are estimated to account for 35.2% of 2025 revenue, or around USD 5.93 billion.

Bevacizumab represents the largest treatment-volume platform, while ramucirumab provides a differentiated VEGFR-2 mechanism.

Ramucirumab inhibits VEGFR-2 and is approved across selected colorectal, gastric/GEJ, liver and lung cancers.

The segment's revenue growth will be moderated by bevacizumab biosimilars even as treatment volume expands.

VEGF-Trap and Fusion-Protein Therapies Represent 1.9%

VEGF-trap and related fusion proteins account for an estimated 1.9%, USD 320 million.

Ziv-aflibercept is the principal established cancer product in this category.

NCI describes ziv-aflibercept as a recombinant VEGFR extracellular-domain fusion protein that binds VEGF and interferes with tumor angiogenesis.

Emerging Bispecific and Other Antiangiogenic Therapies Account for 4.5%

Emerging antiangiogenic modalities represent 4.5% of the modeled market, or around USD 758 million.

This category includes commercially emerging PD-1×VEGF antibodies in Asia together with newer pathway-targeted approaches.

Its share could rise sharply if ivonescimab obtains additional global approvals.

Renal Cell Carcinoma Is the Largest Cancer Segment

Renal cell carcinoma is estimated to account for 24.8% of 2025 angiogenesis-inhibitor revenue, equivalent to around USD 4.18 billion.

RCC has one of the strongest biological and commercial relationships with VEGF-pathway treatment.

Current systemic options incorporate several VEGFR TKIs, including cabozantinib, lenvatinib and axitinib, frequently in combination with immune checkpoint inhibitors.

Colorectal Cancer Represents 22.4%

Colorectal cancer accounts for an estimated 22.4%, USD 3.77 billion.

The market spans bevacizumab products, ramucirumab, ziv-aflibercept, regorafenib and fruquintinib, with zanzalintinib potentially entering after regulatory review.

This depth makes colorectal cancer one of the most competitive antiangiogenesis treatment pathways.

Lung Cancer Accounts for 15.2%

Lung cancer is estimated to represent 15.2% of revenue, or around USD 2.56 billion.

Bevacizumab and ramucirumab have established roles in selected NSCLC populations, while VEGF-related combinations are becoming strategically more important as immunotherapy converges with antiangiogenesis.

Ivonescimab could substantially increase this segment if its PD-1×VEGF mechanism establishes a global NSCLC franchise.

Hepatocellular Carcinoma Accounts for 12.6%

HCC represents an estimated 12.6%, USD 2.12 billion.

The disease has a long history of antiangiogenic treatment involving sorafenib, lenvatinib, cabozantinib and ramucirumab, while contemporary combination therapy increasingly incorporates immunotherapy.

Gynecological Cancers Account for 10.8%

Ovarian, cervical and endometrial cancers collectively generate an estimated 10.8% of market revenue, around USD 1.82 billion.

Bevacizumab is broadly established in ovarian and cervical cancer, while lenvatinib plus pembrolizumab provides an important VEGFR-targeted combination in selected advanced endometrial cancers.

Thyroid, Neuroendocrine and Other Tumors Complete the Market

Thyroid and neuroendocrine tumors represent 7.2% of 2025 revenue, while other cancers including gastric/GEJ tumors and rarer indications account for around 7.0%.

Cabozantinib's 2025 NET approval and Lenvima's established radioactive iodine-refractory thyroid-cancer indication are central to this category.

Cancer Angiogenesis Inhibitors Market Geographical Analysis

North America Leads with 43.0%

North America is estimated to account for 43.0% of global cancer angiogenesis inhibitor revenue in 2025, equivalent to around USD 7.25 billion.

This retains the regional leadership identified on the existing DataM Intelligence page.

The United States is modeled at 38.0% of global revenue, equivalent to around USD 6.40 billion.

The country combines high cancer-treatment expenditure, rapid adoption of VEGFR TKI-checkpoint combinations and extensive access to branded oral oncology medicines.

It is also the principal regulatory market for many next-generation products. Cabometyx received its NET expansion there in March 2025, Jobevne received approval in April 2025, and both zanzalintinib and ivonescimab have 2026 FDA review timelines.

Europe Accounts for 25.6%

Europe represents an estimated 25.6% of global market revenue, USD 4.31 billion in 2025.

Germany is modeled at 5.2% of global revenue, the United Kingdom at 4.2%, France at 3.8%, Italy at 2.7% and Spain at 2.2%.

European oncology systems have broad access to VEGF antibodies and oral TKIs, but biosimilar procurement has a particularly strong influence on bevacizumab economics.

The region should therefore generate strong treatment volumes while showing slower revenue growth in mature antibody segments.

Asia-Pacific Is the Fastest-Growing Region

Asia-Pacific is estimated to account for 23.8% of global revenue, equivalent to about USD 4.01 billion, and is forecast to remain the fastest-growing major regional market, consistent with the legacy DMI positioning.

China is modeled at 7.0% of global market revenue, making it the largest Asia-Pacific market.

The country is increasingly important not only as a treatment market but as a source of antiangiogenesis innovation.

Ivonescimab's August 12, 2026 approval in first-line advanced squamous NSCLC demonstrates China's growing role in the next generation of VEGF-directed oncology.

Japan contributes 5.3% of global revenue, India around 2.8%, South Korea around 2.0% and Australia 1.5%.

Latin America Represents 4.3%

Latin America is estimated to account for around 4.3% of global revenue, USD 725 million.

Brazil represents the largest regional country market at 2.3% of global revenue.

Bevacizumab biosimilars are especially relevant to the region because lower biologic acquisition costs can expand anti-VEGF access where premium branded oncology products remain constrained by reimbursement.

Middle East & Africa Account for 3.3%

Middle East & Africa represent 3.3% of global revenue, or about USD 556 million.

Saudi Arabia, the UAE and Israel represent the highest-value Middle Eastern markets, supported by advanced oncology infrastructure and access to targeted therapy.

South Africa remains an important Sub-Saharan oncology market.

Across the broader region, affordability and access to molecular oncology remain more limiting than availability of the underlying antiangiogenic technologies.

Regional and country figures are DataM Intelligence modeled 2025 estimates.

Cancer Angiogenesis Inhibitors Competitive Landscape

Exelixis

Exelixis has one of the strongest dedicated antiangiogenic oncology franchises through Cabometyx/cabozantinib.

Global cabozantinib franchise net product revenues reached USD 2.9 billion during 2025.

The March 2025 NET approval created an additional commercial growth engine, while zanzalintinib provides a potential successor franchise.

Its February 2026 FDA filing acceptance in metastatic colorectal cancer makes zanzalintinib one of the market's most important near-term pipeline assets.

Eisai and Merck

Eisai's Lenvima remains one of the largest VEGFR-directed oral therapies.

The product spans differentiated thyroid cancer, HCC, RCC and endometrial carcinoma, with the latter two including commercially important pembrolizumab combinations.

Eisai reported USD 1.505 billion in U.S. Lenvima revenue in its fiscal year ended March 2025.

Roche

Roche created the modern anti-VEGF antibody market through Avastin.

The product remains widely used despite biosimilar competition, with Roche reporting CHF 973 million in 2025 sales.

Roche is also strategically relevant to next-generation angiogenesis combinations through atezolizumab-containing regimens, including Exelixis' zanzalintinib development program.

Biocon Biologics and Bevacizumab Biosimilar Suppliers

Biocon joined the U.S. bevacizumab biosimilar market with Jobevne in April 2025.

The product is approved across multiple Avastin-referenced oncology indications.

Amgen, Pfizer and other biosimilar suppliers also participate in the increasingly price-competitive bevacizumab market.

Eli Lilly

Lilly's Cyramza/ramucirumab directly inhibits VEGFR-2 and is used across selected gastric/GEJ, colorectal, HCC and NSCLC settings.

Its antibody-based receptor targeting provides a differentiated mechanism from bevacizumab's direct VEGF-ligand binding.

Summit Therapeutics and Akeso

Summit and Akeso represent the most important emerging disruption through ivonescimab.

The drug combines PD-1 inhibition with VEGF blockade in a single bispecific antibody and is undergoing broad Phase III development across lung cancer and other tumors.

Chinese approval in first-line squamous NSCLC on August 12, 2026, provides important commercial validation of the mechanism.

Other relevant market participants include Pfizer, Bayer, Takeda, Sanofi, Amgen, Ipsen and numerous generic and biosimilar manufacturers.

Recent Cancer Angiogenesis Inhibitors Market Developments

• August 12, 2026: Akeso announced Chinese approval of ivonescimab plus chemotherapy for first-line advanced squamous NSCLC, strengthening commercial validation of combined PD-1/VEGF targeting.
• July 2026: Summit reported updated global Phase III HARMONi results and confirmed that its U.S. ivonescimab BLA remains under FDA review with a November 14, 2026 target action date.
• June 22, 2026: Exelixis reported the final non-liver-metastasis subgroup analysis from STELLAR-303. The overall intent-to-treat population had previously demonstrated a statistically significant overall-survival benefit with zanzalintinib plus atezolizumab versus regorafenib.
• February 2, 2026: FDA accepted Exelixis' NDA for zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer, assigning a December 3, 2026 PDUFA date.
• July 29, 2025: Eisai highlighted approval in China of Lenvima plus pembrolizumab and transarterial chemoembolization for unresectable, non-metastatic HCC, further demonstrating the expansion of VEGFR therapy into multimodal cancer treatment.
• April 10, 2025: FDA approved Jobevne, Biocon Biologics' bevacizumab biosimilar, across multiple oncology indications.
• March 26, 2025: FDA approved Cabometyx for previously treated pancreatic and extra-pancreatic neuroendocrine tumors.

Strategic Opportunity Areas Through 2035

PD-1 × VEGF Bispecific Antibodies

This is the highest-impact white space.

Ivonescimab has already moved into commercial use in China and is under U.S. regulatory review.

Success could encourage additional companies to develop molecules combining immune-checkpoint and angiogenesis inhibition.

Next-Generation VEGFR TKIs

Zanzalintinib demonstrates that the VEGFR TKI class can still generate meaningful innovation after several generations of approved products.

Targeting VEGFR alongside MET and TAM-family kinases may help address resistance and tumor-microenvironment biology.

Biosimilar Bevacizumab Expansion

Bevacizumab biosimilars should increase treatment penetration in emerging and cost-sensitive markets.

The opportunity is primarily volume-driven rather than premium-price-driven.

Jobevne's 2025 FDA approval adds another global-scale manufacturer to this segment.

Immunotherapy-Angiogenesis Combination Sequencing

As checkpoint plus VEGF/VEGFR combinations become standard across additional cancers, physicians increasingly need evidence on sequencing after progression.

The market opportunity therefore extends to therapies that remain active after prior VEGF and PD-1 exposure.

Colorectal Cancer After Standard Therapy

Fruquintinib has already established a dedicated late-line VEGFR treatment market, while zanzalintinib could broaden the category through combination immunotherapy.

Neuroendocrine Tumors

Cabometyx's 2025 approval validates NET as a commercially meaningful antiangiogenic market.

Additional VEGFR programs could target the same disease group as treatment sequencing becomes more sophisticated.

Asia-Pacific Innovation

Asia-Pacific is no longer simply an access-expansion market.

China's rapid commercialization and development of ivonescimab demonstrates that important new antiangiogenic mechanisms can now originate and launch first in Asia before expanding globally.

Why Choose DataM Intelligence?

• DataM Intelligence's refreshed Cancer Angiogenesis Inhibitors Market analysis focuses exclusively on oncology and removes the legacy inclusion of ocular neovascularization.
• The report distinguishes VEGF antibodies and biosimilars, VEGFR/multikinase TKIs, VEGF traps and emerging bispecific therapies rather than relying on outdated pathway categories.
• It examines how the market is moving from stand-alone angiogenesis inhibition toward combinations with immune checkpoint inhibitors and, increasingly, toward single molecules such as PD-1×VEGF bispecific antibodies.
• The competitive analysis captures both mature market pressures-including Avastin biosimilar erosion-and high-growth opportunities involving cabozantinib, zanzalintinib, fruquintinib and ivonescimab.
• Regional analysis separates North America's premium revenue position from Asia-Pacific's combination of expanding access and growing innovation.

Target Audience

Pharmaceutical and biotechnology companies, VEGF/VEGFR drug developers, oncology companies, biosimilar manufacturers, TKI developers, bispecific-antibody companies, immuno-oncology developers, hospitals, comprehensive cancer centers, specialty oncology clinics, contract research organizations, healthcare investors, licensing teams, market-access groups and oncology distributors.